NCT07235878 12-week Magnesium Supplementation on Peri-menopause Symptoms, Cognition, Sleep, and Psychological Well-being
| NCT ID | NCT07235878 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northumbria University |
| Condition | Perimenopause |
| Study Type | INTERVENTIONAL |
| Enrollment | 58 participants |
| Start Date | 2025-12-09 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 58 participants in total. It began in 2025-12-09 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Perimenopause is a transition phase into menopause, characterised by menopausal symptoms while menstrual periods are still occurring. Common symptoms of perimenopause include hot flushes, night sweats, mood swings, anxiety, sleep disturbances, fatigue, and cognitive difficulties. These symptoms can be both frequent and intense, with the potential to significantly deteriorate women's quality of life. Despite an increase in public discourse around menopause, there are still large gaps in knowledge. Previous literature has suggested a relationship between diet and menopause management. However, studies in this area are limited and women often rely on social media for advice on supplements to address menopause complaints. One supplement that has received a lot of attention with purported benefits for menopause is magnesium, primarily due to its links to energy and or/sleep, however no studies have explored psychological effects of magnesium supplementation in perimenopause. The aim of this study is to explore the effects of 12-weeks magnesium supplementation on perimenopause symptoms, cognition, sleep, and psychological well-being.
Eligibility Criteria
Inclusion Criteria: * Self-assess as healthy * Report experiencing troublesome peri-menopause symptoms in the past 6 months but not post-menopausal (defined as 12 months with no periods) Exclusion Criteria: * Post-menopausal * Lactating, pregnant or seeking to become pregnant * Nut Allergy * Taken antidepressant/antianxiety medication or other medication with strong likelihood for effects on cognition or sleep in the past 6 months. * Habitual magnesium supplementation (defined as more than 3 consecutive days or 4 days in total). Will be excluded unless washout for 1 month. * Menopause symptoms have been medically induced. * Receiving gender-affirming hormone therapy.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07235878 clinical trial?
This trial is open to female participants only, aged 40 Years or older, up to 60 Years, studying Perimenopause. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07235878 currently recruiting?
Yes, NCT07235878 is actively recruiting participants. Contact the research team at crystal.haskell-ramsay@northumbria.ac.uk for enrollment information.
Where is the NCT07235878 trial being conducted?
This trial is being conducted at Newcastle upon Tyne, United Kingdom.
Who is sponsoring the NCT07235878 clinical trial?
NCT07235878 is sponsored by Northumbria University. The trial plans to enroll 58 participants.